Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
32 results
D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria
D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117
D2.354 - Questionnaire survey of new treatments for atopic dermatitis
D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria
D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria
D2.357 - Characterizing chronic histaminergic angioedema and chronic urticaria with angioedema, a multicenter Italian experience
D2.358 - Immune shift toward the IL-17 pathway: A case of paradoxical psoriasis in a patient with severe atopic dermatitis induced by dupilumab
D2.359 - Safety and effectiveness of Omalizumab for Cold Urticaria in pediatric age
D2.362 - Dual biological therapy with dupilumab and ixekizumab in a patient with asthma, nasal polyposis, atopic dermatitis and psoriasis
D2.363 - Lanadelumab Effect on Hereditary Angioedema Activity Score: A Tertiary Center Experience
D2.364 - Omalizumab Use in Pediatric Chronic Urticaria, A Retrospective Study from a Tertiary Hospital
D2.430 - Two cases of acquired angioedema: one with splenic lymphoma and the other with Waldenström’s macroglobulinemia
D2.431 - Association of serum IgE levels and atopic status with cancer in the general population
D2.433 - AllergoOncology: Immunocompetent 3D and Skin Organoid Models of Melanoma to Investigate Tumour-Immune Interactions and Immunotherapies
D2.434 - AllergoOncology: Novel crusade for Basophil Activation Test
D2.432 - Blood morphology in health & cancer: comparative, preliminary study on 783 patients
D3.48 - The delabeling of beta-lactam allergy does not change the antibiotic prescribing profile or alerts in Primary Care. The experience of a General Hospital
D3.53 - A retrospective audit of NSAID hypersensitivity in children and young people in a tertiary paediatric allergy centre
D3.55 - Synthetic folic acid allergy
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download